Assessing the Feasibility of a Novel mHealth App in Hematopoietic Stem Cell Transplant Patients.

Journal Article (Journal Article)

Hematopoietic stem cell transplantation (HCT) is a curative treatment option for patients with hematologic conditions but presents many complications that must be managed as a complex, chronic condition. Mobile health applications (mHealth apps) may permit tracking of symptoms in HCT. In seeking strategies to manage the complexities of HCT, our team collaborated with Sicklesoft, Inc., to develop an mHealth app specifically for HCT patients to allow for daily evaluation of patient health, Technology Recordings to better Understand Bone Marrow Transplantation (TRU-BMT). The primary value of this application is that of potentially enhancing the monitoring of symptoms and general health of patients undergoing HCT, with the ultimate goal of allowing earlier detection of adverse events, earlier intervention, and improving outcomes. To first evaluate patient interest in mHealth apps, we designed and administered an interest survey to patients at the 2017 BMT-InfoNet reunion. As a follow-up to the positive feedback received, we began testing the TRU-BMT app in a Phase 1 pilot study. Thirty patients were enrolled in this single-arm study and were given the TRU-BMT mHealth app on a smartphone device in addition to a wearable activity tracker. Patients were followed for up to 180 days, all the while receiving daily app monitoring. Adherence to TRU-BMT was approximately 30% daily and 44% weekly, and greater adherence was associated with increased meal completion, decreased heart rate, and shorter hospital stay. TRU-BMT assessments of symptom severity were significantly associated with duration of hospital stay and development of chronic graft-versus-host disease. Our findings suggest that using TRU-BMT throughout HCT is feasible for patients and established a proof-of-concept for a future randomized control trial of the TRU-BMT application in HCT. © 2021 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Full Text

Duke Authors

Cited Authors

  • Racioppi, A; Dalton, T; Ramalingam, S; Romero, K; Ren, Y; Bohannon, L; Arellano, C; Jonassaint, J; Miller, H; Barak, I; Fish, LJ; Choi, T; Gasparetto, C; Long, GD; Lopez, RD; Rizzieri, DA; Sarantopoulos, S; Horwitz, ME; Chao, NJ; Shah, NR; Sung, AD

Published Date

  • February 2021

Published In

  • Transplant Cell Ther

Volume / Issue

  • 27 / 2

Start / End Page

  • 181.e1 - 181.e9

PubMed ID

  • 33830035

Electronic International Standard Serial Number (EISSN)

  • 2666-6367

Digital Object Identifier (DOI)

  • 10.1016/j.jtct.2020.10.017

Language

  • eng